SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.
We are developing our lead product candidate, SCY-078, a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
|Nov 16, 2017
SCYNEXIS Appoints Scott Sukenick as General Counsel
|Nov 7, 2017
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
|Oct 5, 2017
SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017